Abstract:Although depression has been studied for many decades, the exact mechanisms that lead to depression are still unknown, and available treatments only help a fraction of patients. In the 1960s, the serotonin hypothesis was published, suggesting that serotonin is the key player in depression. However, this hypothesis is being increasingly doubted. In this review, we aim to contribute to the ongoing debate on the involvement of serotonin in depression. We review the evolution of antidepressant treatments, systemic research over the years, and future research applications that will help to bridge the gap between systemic research and neurotransmitter dynamics using biosensors. Depression is one of the most common psychiatric disorders worldwide, affecting approximately 280 million people, with probably much higher unrecorded cases. Depression is associated with symptoms such as anhedonia, feelings of hopelessness, sleep disturbances, and even suicidal thoughts. Tragically, more than 700 000 people commit suicide each year. Although depression has been studied for many decades, the exact mechanisms that lead to depression are still unknown, and available treatments only help a fraction of patients. In the late 1960s, the serotonin hypothesis was published, suggesting that serotonin is the key player in depressive disorders. However, this hypothesis is being increasingly doubted as there is evidence for the influence of other neurotransmitters, such as noradrenaline, glutamate, and dopamine, as well as larger systemic causes such as altered activity in the limbic network or inflammatory processes. In this narrative review, we aim to contribute to the ongoing debate on the involvement of serotonin in depression. We will review the evolution of antidepressant treatments, systemic research on depression over the years, and future research applications that will help to bridge the gap between systemic research and neurotransmitter dynamics using biosensors. These new tools in combination with systemic applications, will in the future provide a deeper understanding of the serotonergic dynamics in depression.

The neurobiology of depression—revisiting the serotonin hypothesis. II. Genetic, epigenetic and clinical studies

The neurobiology of depression—revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms

Revisiting the Serotonin Hypothesis: Implications for Major Depressive Disorders

Genetic, epigenetic and posttranscriptional mechanisms for treatment of major depression: the 5-HT1A receptor gene as a paradigm

Serotonergic gene expression and depression: implications for developing novel antidepressants

Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression

The role of serotonin in depression—A historical roundup and future directions

Epigenetics and depressive disorders: a review of current progress and future directions

New insights into the neurobiological mechanisms of major depressive disorders

The genetics of selective serotonin reuptake inhibitors

The molecular neurobiology of depression

The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants

Stress, genetics and epigenetic effects on the neurobiology of suicidal behavior and depression

The neurobiology of depression: An integrated view

Depression research: where are we now?

Neurobiological Investigation of Depression: Unraveling the Biological Basis of a Complex Mental Health Challenge

Understanding the pathophysiology of depression: From monoamines to the neurogenesis hypothesis model - are we there yet?

Depressive disorder and antidepressants from an epigenetic point of view

The role of 5-HT receptors in depression

The involvement of serotonin in major depression: nescience in disguise?